Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Clinical Data
  • ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come
  • Clinical Data

ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come

BioSpace

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology's annual conference but its biggest data are expected later this year.

Oncology

Read full story

pharminent June 2, 2026 (Last updated: June 3, 2026)

BioSpace

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year.

Oncology

Read full story

Post navigation

Previous: FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
Next: ASCO26: In vivo oncology approaches continue to show promise

Related Stories

  • Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026
  • Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026
  • Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.